A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

Kelly L. Sullivan

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

Kelly L. Sullivan

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Other contribution › Other

Original language	American English
State	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Disciplines

Epidemiology
Public Health

Cite this

@misc{7e376b9f84874575ba7fb186d7326732,

title = "A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy",

author = "Sullivan, \{Kelly L.\}",

note = "Kelly L. Sullivan (Sub-Investigator), {"}A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy,{"} Allon Therapeutics, Inc. (2011-2012).",

year = "2011",

language = "American English",

type = "Other",

}

TY - GEN

T1 - A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

AU - Sullivan, Kelly L.

N1 - Kelly L. Sullivan (Sub-Investigator), "A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy," Allon Therapeutics, Inc. (2011-2012).

PY - 2011

Y1 - 2011

UR - https://clinicaltrials.gov/ct2/show/NCT01110720

M3 - Other

ER -

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

UN SDGs

Disciplines

Other files and links

Cite this